Advanced Heart Failure References

Aleksova N, Chih S. The role of durable left ventricular assist devices in advanced heart failure: Would my patient benefit? Can J Cardiol. 2017;33:540–3.

Allen LA, Gheorghiade M, Reid KJ, Dunlay SM, Chan PS, Hauptman PJ, et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circ Cardiovasc Qual Outcomes. 2011;4:389–98.

Amaya E, Taya M. Is exercise training appropriate for patients with advanced heart failure receiving continuous inotropic infusion? A review. Clin Med Insights Cardiol. 2018;12:1179546817751438.

Baeza-Trinidad R, Mosquera-Lozano JD. Bendopnea: The next prognostic marker of advanced heart failure? Am Heart J. 2017;186:e1.

Barbici I, Hedman A, Ewaldsson C-A. Use of levosimendan in patients with heart failure in different settings: case reports and treatment guidance. Heart Lung Vessel. 2015;7:143–50.

Baumwol J. “I Need Help” – A mnemonic to aid timely referral in advanced heart failure. J Heart Lung Transplant. 2017;36:593–4.

Brubaker PH, Kitzman DW. Chronotropy: the Cinderella of heart failure pathophysiology and management. JACC Heart Fail. 2013;1:267–9.

Cameli M, Incampo E, Navarri R, Mandoli GE, Sciaccaluga C, Righini FM, Effects of levosimendan in heart failure: The role of echocardiography. Echocardiography. 2019;36:1566–72.

Carey SA, Tecson KM, Bass K, Felius J, Hall SA. Patient activation with respect to advanced heart failure therapy in patients over age 65 years. Heart Lung. 2018;47:285–9.

Chaudhry SP, Stewart GC. Advanced heart failure: prevalence, natural history, and prognosis. Heart Fail Clin. 2016;12:323–33.

Comín-Colet J, Manito N, Segovia-Cubero J, Delgado J, García Pinilla JM, Almenar L, et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail. 2018;20:1128–36.

Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018; [Epub ahead of print].

Crespo Leiro MG, Paniagua Martín MJ. Management of advanced or refractory heart failure. Rev Esp Cardiol. 2004;57:869–83.

Cross SH, Kamal AH, Taylor DH, Warraich HJ. Hospice use among patients with heart failure. Card Fail Rev. 2019;5:93–8.

Dev S, Abernethy AP, Rogers JG, O'Connor CM. Preferences of people with advanced heart failure – a structured narrative literature review to inform decision making in the palliative care setting. Am Heart J. 2012;164:313–319.e5.

Dolgin M, Association NYH, Fox AC, Gorlin R, Levin RI, New York Heart Association. Criteria Committee. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston, MA: Lippincott Williams and Wilkins; March 1, 1994.

Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ. 2005;330:625.

Drazner MH, Brown RH, Kaiser PA, Cabuay B, Lewis NP, Semigran MJ, et al. Relationship of right- and left-sided filling pressures in patients with advanced heart failure: a 14-year multi-institutional analysis. J Heart Lung Transplant. 2012;31:67–72.

Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med. 2001;345:574–81.

Fendler TJ, Nassif ME, Kennedy KF, Joseph SM, Silvestry SC, Ewald GA, et al. Global outcome in patients with left ventricular assist devices. Am J Cardiol. 2017;119:1069–73.

Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146-56.

Fruhwald S, Pollesello P, Fruhwald F. Advanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations. Exp Rev Cardiovasc Ther. 2016;14:1335–47.

García Peña AA, Rodriguez MFB, Baron AM, Mariño A. Is levosimendan infusion useful in patients with advanced heart failure? Meta-analysis and systematic review. J Heart Health 2018;5:1–5.

Gustafsson F, Rogers JG. Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes. Eur J Heart Fail. 2017;19:595–602.

Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein Hu, et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol. 2002;90:29–34.

Kochav SM, Flores RJ, Truby LK, Topkara VK. Prognostic impact of Pulmonary Artery Pulsatility Index (PAPi) in patients with advanced heart failure: Insights from the ESCAPE trial. J Card Fail. 2018. [Epub ahead of print].

Komamura K. Similarities and differences between the pathogenesis and pathophysiology of diastolic and systolic heart failure. Cardiol Res Pract. 2013;2013:824135.

Kopustinskiene DM, Pollesello P, Saris NE. Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol. 2004;68:807–12.

Krabatsch T, Netuka I, Schmitto JD, Zimpfer D, Garbade J, Rao V, et al. Heartmate 3 fully magnetically levitated left ventricular assist device for the treatment of advanced heart failure – 1 year results from the CE Mark trial. J Cardiothorac Surg. 2017;12:23.

Lewin WH, Cheung W, Horvath AN, Haberman S, Patel A, Sullivan D. Supportive cardiology: Moving palliative care upstream for patients living with advanced heart failure. J Palliat Med. 2017;20:1112-9.

Li KFA, Mok KH, Chia YW. Use of levosimendan in acute decompensated anthracycline-induced cardiomyopathy. Acute Cardiovascular Care, Barcelona, Spain, 2019: P745.

Li J, Wang XY, Yang ZY, Li Y, Yang F, Yuan P, et al. The efficacy of simendan in the treatment of acute heart failure and its impact on NT-proBNP. Eur Rev Med Pharmacol Sci. 2019;23:4027–32. 

Lowey SE. Palliative Care in the Management of Patients with Advanced Heart Failure. Adv Exp Med Biol. 2017;1067:295–311.

Lum YH, McKenzie S, Brown M, Hamilton-Craig C. Impact of cardiac MRI in heart failure patients referred to a tertiary advanced heart failure unit: improvements in diagnosis and management. Intern Med J. 2018. [Epub ahead of print].

Lund LH, Trochu JN, Meyns B, Caliskan K, Shaw S, Schmitto JD, et al. Screening for heart transplantation and left ventricular assist system: results from the ScrEEning for advanced Heart Failure treatment (SEE-HF) study. Eur J Heart Fail. 2018;20:152–60.

MacIver J, Wentlandt K, Ross HJ. Measuring quality of life in advanced heart failure. Curr Opin Support Palliat Care. 2017;11:12–6.

Madan SA, Fida N, Barman P, Sims D, Shin J, Verghese J, et al. Frailty assessment in advanced heart failure. J Card Fail. 2016 Oct;22:8404.

Marti CN, Georgiopoulou VV, Kalogeropoulos AD. Acute heart failure: patient characteristics and pathophysiology. Curr Heart Fail Rep. 2013;10:427–33.

Marwick TH. Methods used for the assessment of LV systolic function: common currency or tower of Babel? Heart. 2013;99:1078–86.

Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. J Heart Lung Transplant. 2016;35:1–23.

Mehra MR, Salerno C, Cleveland JC, Pinney S, Yuzefpolskaya M, Milano CA, et al. Health care resource use and cost implications in the MOMENTUM 3 long-term outcome study: a randomized controlled trial of a magnetically levitated cardiac pump in advanced heart failure. Circulation. 2018. [Epub ahead of print].

Mentz RJ & O'Connor. Pathophysiology and clinical evaluation of acute heart failure. Nat Rev Cardiol. 2016;13:28–35.

Metra M, Ponikowski P, Dickstein K, McMurray JJV, Gavazzi A, Bergh C-H, et al. Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2007;9:684–94.

Moayedi Y, Duero Posada JG, Foroutan F, Goldraich LA, Alba AC, MacIver J, et al. The prognostic significance of frailty compared to peak oxygen consumption and B-type natriuretic peptide in patients with advanced heart failure. Clin Transplant. 2018;32.

Nakanishi M, Nakao K, Kumasaka L, Arakawa T, Fukui S, Ohara T, et al. Improvement in exercise capacity by exercise training associated with favorable clinical outcomes in advanced heart failure with high B-type natriuretic peptide level. Circ J. 2017;81:130714.

Nieminen MS, Altenberger J, Ben-Gal T, Böhmer A, Comin-Colet J, Dickstein K, et al. Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus. Int J Cardiol. 2014;174:360–7.

Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA. 2002;287:628–40.

Norton C, Georgiopoulou VV, Kalogeropoulos AP, et al. Epidemiology and cost of advanced heart failure. Prog Cardiovasc Dis. 2011;54:78–85.

Oliva F, Perna E, Marini M, Nassiacos D, Cirò A, Malfatto G, et al. Scheduled intermittent inotropes for Ambulatory Advanced Heart Failure. The RELEVANT-HF multicentre collaboration. Int J Cardiol. 2018;272:255–9.

Ortis B, Villani A, Oldani M, Giglio A, Ciambellotti F, Facchini M, et al. Intermittent levosimendan infusions in advanced heart failure: a real world experience. J Int Med Res. 2017;45:361–71.

Orzechowski R, Galvão AL, Nunes TDS, Campos LS. Palliative care need in patients with advanced heart failure hospitalized in a tertiary hospital. Rev Esc Enferm USP. 2019;53:e03413.

Pashkovetsky E, Aggarwal C, Aronow GWS. Use of levosimendan in acute and advanced heart failure: short review on available real-world data. Ther Clin Risk Manag. 2019;15:765–72.

Pölzl G, Altenberger J, Baholli L, Beltrán P, Borbély A, Comin-Colet J, et al. Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy. Int J Cardiol. 2017;243:389–95.

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975.

Rogers JG, Pagani FD, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, et al. Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med. 2017;376:451–60.

Rosenberg MA, Manning WJ. Diastolic dysfunction and risk of atrial fibrillation: A mechanistic appraisal. Circulation. 2012;126:2353–62.

Schmitto JD, Zimpfer D, Fiane AE, Larbalestier R, Tsui S, Jansz P, et al. Long-term support of patients receiving a left ventricular assist device for advanced heart failure: a follow-up analysis of the Registry to Evaluate the HeartWare Left Ventricular Assist System. Eur J Cardiothorac Surg. 2016;50:834–8.

Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007;154:260–6.

Silvetti S, Belletti A, Fontana A, Pollesello P. Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials. ESC Heart Fail. 2017;4:595–604.

Silvetti S, Nieminen MS. Repeated or intermittent levosimendan treatment in advanced heart failure: an updated meta-analysis. Int J Cardiol. 2016;202:138–43.

Stehlik J, Estep JD, Selzman CH, Rogers JG, Spertus JA, Shah KB, et al. Patient-reported health-related quality of life is a predictor of outcomes in ambulatory heart failure patients treated with left ventricular assist device compared with medical management: results from the ROADMAP study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management). Circ Heart Fail. 2017;10:pii.e003910.

Solís García Del Pozo J, Olmeda Brull C, de Arriba Méndez JJ, Corbí Pascual M. Palliative medicine for patients with advanced heart failure: New evidence. Rev Clin Esp. 2019;219(6):332–341.

Szczurek W, Szygula-Jurkiewicz B, Siedlecki L, Gąsior M. Prognostic scales in advanced heart failure. Kardiochir Torakochirurgia Pol. 2018;15:183–7.

Szilágyi S, Pollesello P, Levijoki J, Kaheinen P, Haikala H, Edes I, et al. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol. 2004;486:67–74.

Szyguła-Jurkiewicz B, Siedlecki Ł, Pyka Ł, Romuk E, Przybyłowski P, Gąsior M. Red blood cell distribution width, relative lymphocyte count, and type 2 diabetes predict all‑cause mortality in patients with advanced heart failure. Pol Arch Intern Med. 2018;128:115–20.

Tainter CR, Braun OÖ, Teran F, Nguyen AP, Robbins K, O'Brien EO, et al. Emergency department visits among patients with left ventricular assist devices. Intern Emerg Med. 2017. [Epub ahead of print].

Taya M, Amiya E, Hatano M, Maki H, Nitta D, Saito A, et al. High-intensity aerobic interval training can lead to improvement in skeletal muscle power among in-hospital patients with advanced heart failure. Heart Vessels. 2018;33:752–9.

Taylor GJ, Lee DM, Baicu CF, Zile MR. Palliative care for advanced heart failure in a Department of Veterans Affairs regional hospice program: Patient selection, a treatment protocol, and clinical course. J Palliat Med. 2017;20:1068–73.

Thibodeau JT, Jenny BE, Maduka JO, Divanji PH, Ayers CR, Araj F, et al. Bendopnea and risk of adverse clinical outcomes in ambulatory patients with systolic heart failure. Am Heart J. 2017;183:102–7.

UretskyBF, Thygesen K, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation. 2000;120:611–6.

Weerahandi H, Goldstein N, Gelfman LP, Jorde U, Kirkpatrick JN, Meyerson E, et al. The relationship between psychological symptoms and ventricular assist device implantation. J Pain Symptom Manage. 2017;5:870–6.

WHO, 2014. Global atlas of palliative care at the end of life. Available at (accessed September 2019).

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147–239.

Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol. 1997;333:249–59.

Yost G, Bhat G, Mahoney E, Tatooles A. Reduced anxiety and depression in patients with advanced heart failure after left ventricular assist device implantation. Psychosomatics. 2017;58:406–14.



Medical information for healthcare professionals about acute and advanced heart failure. Find relevant resources, links, publications, videos and events.

Acute Heart Failure

Acute Heart Failure

Explore a comprehensive guide to the epidemiology, pathophysiology, signs, symptoms, diagnosis, prognosis and treatment of acute heart failure.


Login/ Register Maximise Minimise